These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 31652100)
41. Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors. Coppens R; Yang J; Ghosh S; Gill J; Chambers C; Easaw JC J Oncol Pharm Pract; 2019 Sep; 25(6):1366-1373. PubMed ID: 30124122 [TBL] [Abstract][Full Text] [Related]
42. Short-term Withdrawal of Levothyroxine, Induced Increase of Thyroid-stimulating Hormone and an Increase Ratio of Triiodothyronine to Thyroxine. Carlwe M; Schaffer T; Sjöberg S Eur Endocrinol; 2013 Mar; 9(1):37-39. PubMed ID: 30349609 [No Abstract] [Full Text] [Related]
43. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Uy HL; Reasner CA; Samuels MH Am J Med; 1995 Aug; 99(2):173-9. PubMed ID: 7625422 [TBL] [Abstract][Full Text] [Related]
44. Glucose-induced paradoxical hyperkalemia in patients with suppression of the renin-aldosterone system: prevention by sodium depletion. Radó JP J Endocrinol Invest; 1979; 2(4):401-6. PubMed ID: 395185 [TBL] [Abstract][Full Text] [Related]
45. Rhabdomyolysis after withdrawal of thyroid hormone in a patient with papillary thyroid cancer. Espiritu RP; Stan MN Endocr Pract; 2008 Nov; 14(8):1023-6. PubMed ID: 19095604 [TBL] [Abstract][Full Text] [Related]
49. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Haugen BR; Pacini F; Reiners C; Schlumberger M; Ladenson PW; Sherman SI; Cooper DS; Graham KE; Braverman LE; Skarulis MC; Davies TF; DeGroot LJ; Mazzaferri EL; Daniels GH; Ross DS; Luster M; Samuels MH; Becker DV; Maxon HR; Cavalieri RR; Spencer CA; McEllin K; Weintraub BD; Ridgway EC J Clin Endocrinol Metab; 1999 Nov; 84(11):3877-85. PubMed ID: 10566623 [TBL] [Abstract][Full Text] [Related]
50. Reduction of erythrocyte (Na(+)-K+) ATPase activities in non-insulin-dependent diabetic patients with hyperkalemia. Mimura M; Makino H; Kanatsuka A; Yoshida S Metabolism; 1992 Apr; 41(4):426-30. PubMed ID: 1313528 [TBL] [Abstract][Full Text] [Related]
51. Effects of thyroid status on thyroid autoimmunity expression in euthyroid and hypothyroid patients with Hashimoto's thyroiditis. Rieu M; Richard A; Rosilio M; Laplanche S; Ropion V; Fombeur JP; Berrod JL Clin Endocrinol (Oxf); 1994 Apr; 40(4):529-35. PubMed ID: 8187321 [TBL] [Abstract][Full Text] [Related]
52. Association between thyroid function and lipid profiles, apolipoproteins, and high-density lipoprotein function. Jung KY; Ahn HY; Han SK; Park YJ; Cho BY; Moon MK J Clin Lipidol; 2017; 11(6):1347-1353. PubMed ID: 28958565 [TBL] [Abstract][Full Text] [Related]
53. Analysis of the incidence and influencing factors of hyponatremia before Cao JJ; Yun CH; Xiao J; Liu Y; Wei W; Zhang W World J Clin Cases; 2021 Dec; 9(36):11173-11182. PubMed ID: 35071548 [TBL] [Abstract][Full Text] [Related]
54. Thyroid hormone status and pituitary function in adult rats given oral doses of perfluorooctanesulfonate (PFOS). Chang SC; Thibodeaux JR; Eastvold ML; Ehresman DJ; Bjork JA; Froehlich JW; Lau C; Singh RJ; Wallace KB; Butenhoff JL Toxicology; 2008 Jan; 243(3):330-9. PubMed ID: 18063289 [TBL] [Abstract][Full Text] [Related]
55. Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance. Jojima T; Shinzawa T; Ohira E; Sakurai S; Tomaru T; Iijima T; Kogai T; Usui I; Aso Y Endocr J; 2022 Aug; 69(8):941-945. PubMed ID: 35249899 [TBL] [Abstract][Full Text] [Related]
56. The renin-angiotensin system in hypothyroidism of short duration. Elias AN; Kyaw T; Valenta LJ; Meshkinpour H Horm Metab Res; 1986 May; 18(5):349-51. PubMed ID: 3522392 [TBL] [Abstract][Full Text] [Related]
57. Serum microRNA profiles in athyroid patients on and off levothyroxine therapy. Massolt ET; Chaker L; Visser TJ; Gillis AJM; Dorssers LCJ; Beukhof CM; Kam BLR; Franssen GJ; Brigante G; van Ginhoven TM; Visser WE; Looijenga LHJ; Peeters RP PLoS One; 2018; 13(4):e0194259. PubMed ID: 29649216 [TBL] [Abstract][Full Text] [Related]
58. Serum thyroxine and thyroid-stimulating hormone concentration in hyperthyroid cats that develop azotaemia after radioiodine therapy. Peterson ME; Nichols R; Rishniw M J Small Anim Pract; 2017 Sep; 58(9):519-530. PubMed ID: 28661007 [TBL] [Abstract][Full Text] [Related]
59. Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal. Huang SC; Wu VC; Lin SY; Sheu WH; Song YM; Lin YH; Wu CC; Chang WD Thyroid; 2009 Jan; 19(1):13-20. PubMed ID: 19072673 [TBL] [Abstract][Full Text] [Related]
60. Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. Kuijt WJ; Huang SA J Clin Endocrinol Metab; 2005 Nov; 90(11):6123-5. PubMed ID: 16091480 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]